Bill Wexler's Dog Pound Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound

REFR 1.554

-4.1%

Dec 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Trocchi who wrote (8500)	1/22/2002 4:04:26 PM
From: BDR	Read Replies (2) of 10293

Speaking of outlandish statements, what about: "Despite its relatively small size and short corporate history (ten years), Vivus already has proven its ability to rapidly develop a drug for a sexual condition that historically has been misunderstood, under-diagnosed and for which there are no currently approved products. Vivus accomplished this first in the mid 1990s with the rapid development and approval of MUSE. With the FDA’s approval yesterday of the IND for TA-1790, Vivus now can begin U.S. clinical studies of TA-1790, an orally administered PDE-5 inhibitor to treat erectile dysfunction (ED). As a result, Vivus is on track to have two of its lead compounds in pivotal studies by year-end." From the context I gather the analyst is talking about impotence. Someone needs to tell the him about a little drug called Viagra, Caverject, Tri-Mix, etc. This sounds like the BS associated with Vivus and Zonagen in the past. Simply ignore reality and promote like hell.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next